Related Experiment Videos
The effect of physostigmine on diazepam-induced ventilatory depression: a double-blind study
Anesthesiology
|November 1, 1984
Summary
Physostigmine salicylate may increase awareness but decrease ventilatory drive in healthy subjects sedated with diazepam. This ventilatory depression suggests caution when using physostigmine in patients who have received diazepam.
Area of Science:
- Pharmacology
- Neuroscience
- Respiratory Physiology
Background:
- Diazepam, a benzodiazepine, is known to suppress respiratory drive.
- Physostigmine, a cholinesterase inhibitor, can reverse some central nervous system effects of benzodiazepines.
Purpose of the Study:
- To investigate the effects of physostigmine salicylate on ventilatory response to carbon dioxide (VE RCO2) and awareness in healthy subjects previously sedated with diazepam.
- To assess the potential of physostigmine to counteract diazepam-induced respiratory depression.
Main Methods:
- A double-blind, placebo-controlled, crossover study design was employed.
- Healthy subjects received diazepam followed by either physostigmine salicylate or saline placebo.
- Ventilatory response to carbon dioxide and level of consciousness were measured.
Main Results:
- Diazepam significantly decreased the slope of VE RCO2, indicating reduced ventilatory drive.
- Physostigmine administration resulted in a further decrease in VE RCO2 slope, unlike the saline placebo which showed an increase.
- Level of consciousness significantly increased after physostigmine compared to saline.
Conclusions:
- While physostigmine may improve awareness after diazepam sedation, it also exacerbates the reduction in ventilatory drive.
- The combined effect of physostigmine and diazepam on respiratory control may limit the therapeutic utility of physostigmine in this context.